:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Yichen Yan, Ruitao Lin, Tianyu Guan, Haolun Shi, Xiaolei Lin
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Statistics in Medicine
Online Access:	https://onlinelibrary.wiley.com/doi/10.1002/sim.70049
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
by: Cheng‐Han Yang, et al.
Published: (2026)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
by: Yingjie Qiu, et al.
Published: (2026)

Two‐Stage Double‐Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region
by: Jiashan He, et al.
Published: (2026)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
by: Meizi Liu, et al.
Published: (2025)

Drift Parameter Based Sample Size Determination in Multi‐Stage Bayesian Randomized Clinical Trials
by: Yueyang Han, et al.
Published: (2025)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
by: Rebecca B. Silva, et al.
Published: (2024)

Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
by: Peng Yang, et al.
Published: (2024)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
by: Chloe E. Falke, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Identification of Regions of Interest in Neuroimaging Data With Irregular Boundary Based on Semiparametric Transformation Models and Interval‐Censored Outcomes
by: Chun Yin Lee, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
by: Hakim‐Moulay Dehbi, et al.
Published: (2025)

REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors
by: Cheng‐Han Yang, et al.
Published: (2024)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
by: Jiaqi Tong, et al.
Published: (2025)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
by: Holger Dette, et al.
Published: (2025)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

Supervised Functional Principal Component Analysis Under the Mixture Cure Rate Model: An Application to Alzheimer'S Disease
by: Jiahui Feng, et al.
Published: (2025)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
by: Kendra Davis‐Plourde, et al.
Published: (2025)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
by: Xinran Huang, et al.
Published: (2024)

A class of computational methods to reduce selection bias when designing Phase 3 clinical trials
by: Tianyu Zhan
Published: (2024)

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies
by: Kai Chen, et al.
Published: (2025)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
by: David S. Robertson, et al.
Published: (2025)

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule
by: Juhee Lee, et al.
Published: (2024)

Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies
by: Lukas A. Widmer, et al.
Published: (2025)

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
by: Erik W. van Zwet, et al.
Published: (2026)

An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing With Concurrent Controls in Platform Trials
by: Tianyu Zhan, et al.
Published: (2025)

A General Framework for Designing and Evaluating Active‐Controlled Trials with Non‐Inferiority Objectives
by: Antonio Olivas‐Martinez, et al.
Published: (2026)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
by: Ethan Ashby, et al.
Published: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
by: Hyejung Jung, et al.
Published: (2026)

RMST for Interval‐Censored Data in Oncology Clinical Trials
by: Xiyuan Gao, et al.
Published: (2025)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
by: Fei Gao, et al.
Published: (2025)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
by: Tianyu Zhan, et al.
Published: (2026)

Variability in Causal Effects and Noncompliance in a Multisite Trial: A Bivariate Hierarchical Generalized Random Coefficients Model for a Binary Outcome
by: Xinxin Sun, et al.
Published: (2024)

The Design of Large‐Scale Plasma Donation Trials
by: Kecheng Li, et al.
Published: (2025)

Adaptive Seamless Phase II / III Randomization Test Considering Treatment Group Selection Based on Short–Term Binary Outcomes
by: Funato Sato, et al.
Published: (2026)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
by: Yuan Li, et al.
Published: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
by: Shu Jiang, et al.
Published: (2025)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
by: Daniel Backenroth, et al.
Published: (2026)